CoChat

Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience

Open access
Folkes, Alecia S., Feng, Mingye, Zain, Jasmine M., Abdulla, Farah, Rosen, Steven T., Querfeld, Christiane · 2018 · Current Opinion in Oncology
Cited by 72

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Purpose of review: To describe the relevance of CD47 in the tumor microenvironment and summarize data on anti-CD47 therapies, including its role in cutaneous T-cell lymphoma (CTCL). Recent findings: CD47 is expressed on all normal cells and targets SIRPα on the surface of myeloid cells. However, CD47 is found to be overexpressed on cancer cells. CD47–SIRPα interaction inhibits macrophage phagocytosis, allowing cancer cells to escape immune surveillance. Current focus in immunotherapy has been targeted toward inhibiting CD47–SIRPα interaction via anti-CD47 antibodies. This activates innate immunity, promoting cancer cell destruction by macrophages. It also activates adaptive immunity resulting in antigen-presentation, mostly by dendritic cells, leading to antitumor cytotoxic reactions. Current CD47 antagonists undergoing clinical trials include Hu5F9 (an anti-CD47 antibody that directly inhibits the CD47–SIRPα interaction) and TTI-621, (a fusion protein composed of CD47 binding domain of human SIRPα and linked to the Fc region of IgG1). These agents have continued to show strong efficacy against solid and hematological tumors. Summary: In the CTCL tumor microenvironment, increased immune checkpoint inhibition expression via CD47 bound to SIRPα correlates with a more advanced disease state. Continued success in treating these patients requires further studies on CD47 antagonists, specifically when combined with other antibodies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/cco.0000000000000468

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 72

Metadata

Authors
Folkes, A. S., Feng, M., Zain, J. M., Abdulla, F., Rosen, S. T., & Querfeld, C.
Venue
Current Opinion in Oncology
Published
2018-09
Volume
30
Issue
5
Pages
332-337
ISSN
  • 1040-8746 (ISSN-L)
  • 1531-703X
OpenAlex
W2878837766
Cited by
72
References
4
FWCI
4.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience. https://app.cochat.ai/papers/10.1097/cco.0000000000000468
The paper
Folkes, A. S., Feng, M., Zain, J. M., Abdulla, F., Rosen, S. T., & Querfeld, C. (2018). Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience. Current Opinion in Oncology. https://doi.org/10.1097/cco.0000000000000468

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.